Parkinson Disease Drug Industry Research Report 2024

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,950	104 Pages	APO Research, Inc.	February, 2024	APRC18569578

Best Price Guarantee
Price	from $2,950
Length	104 Pages
Publisher	APO Research, Inc.
Published Date	February, 2024
SKU	APRC18569578

Parkinson Disease Drug Industry Research Report 2024

Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.

Highlights

The global Parkinson Disease Drug market is projected to reach US$ million by 2030 from an estimated US$ million in 2024, at a CAGR of % during 2025 and 2030.
Global Parkinson Disease Drug key players include Merck, Akorn, GSK, Boehringer Ingelheim, Teva Pharmaceutical, etc.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Parkinson Disease Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Parkinson Disease Drug.
The Parkinson Disease Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Parkinson Disease Drug market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Parkinson Disease Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Merck
Akorn
GSK
Novartis
Boehringer Ingelheim
Teva Pharmaceutical
Abbvie
Kyowa Hakko Kirin Pharma
Astellas Pharma
Desitin Arzneimittel
Endo Pharmaceuticals
F.Hoffmann-La Roche
H.Lundbeck
Valeant
Apokyn
Orion
Stada Arzneimittel
US WorldMeds
Bausch Health

Product Type Insights

Global markets are presented by Parkinson Disease Drug type, along with growth forecasts through 2030. Estimates on revenue are based on the price in the supply chain at which the Parkinson Disease Drug are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2019-2024) and forecast period (2025-2030).
Parkinson Disease Drug segment by Type

Sinemet-CR
Trastal
Madopar
COMT Inhibitor
Other

Application Insights

This report has provided the market size (revenue data) by application, during the historical period (2019-2024) and forecast period (2025-2030).
This report also outlines the market trends of each segment and consumer behaviors impacting the Parkinson Disease Drug market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Parkinson Disease Drug market.
Parkinson Disease Drug Segment by Application
Under 40 Years Old
40-65 Years Old
Above 65 Years Old

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2019-2030.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2023 because of the base year, with estimates for 2024 and forecast revenue for 2030.

North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Parkinson Disease Drug market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Parkinson Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Parkinson Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Parkinson Disease Drug industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Parkinson Disease Drug.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Parkinson Disease Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

1 Preface: 1.1 Scope of Report; 1.2 Reasons for Doing This Study; 1.3 Research Methodology; 1.4 Research Process; 1.5 Data Source; 1.5.1 Secondary Sources; 1.5.2 Primary Sources
2 Market Overview: 2.1 Product Definition; 2.2 Parkinson Disease Drug by Type; 2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030); 1.2.2 Sinemet-CR; 1.2.3 Trastal; 1.2.4 Madopar; 1.2.5 COMT Inhibitor; 1.2.6 Other; 2.3 Parkinson Disease Drug by Application; 2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030); 2.3.2 Under 40 Years Old; 2.3.3 40-65 Years Old; 2.3.4 Above 65 Years Old; 2.4 Assumptions and Limitations
3 Parkinson Disease Drug Breakdown Data by Type: 3.1 Global Parkinson Disease Drug Historic Market Size by Type (2019-2024); 3.2 Global Parkinson Disease Drug Forecasted Market Size by Type (2025-2030)
4 Parkinson Disease Drug Breakdown Data by Application: 4.1 Global Parkinson Disease Drug Historic Market Size by Application (2019-2024); 4.2 Global Parkinson Disease Drug Forecasted Market Size by Application (2019-2024)
5 Global Growth Trends: 5.1 Global Parkinson Disease Drug Market Perspective (2019-2030); 5.2 Global Parkinson Disease Drug Growth Trends by Region; 5.2.1 Global Parkinson Disease Drug Market Size by Region: 2019 VS 2023 VS 2030; 5.2.2 Parkinson Disease Drug Historic Market Size by Region (2019-2024); 5.2.3 Parkinson Disease Drug Forecasted Market Size by Region (2025-2030); 5.3 Parkinson Disease Drug Market Dynamics; 5.3.1 Parkinson Disease Drug Industry Trends; 5.3.2 Parkinson Disease Drug Market Drivers; 5.3.3 Parkinson Disease Drug Market Challenges; 5.3.4 Parkinson Disease Drug Market Restraints
6 Market Competitive Landscape by Players: 6.1 Global Top Parkinson Disease Drug Players by Revenue; 6.1.1 Global Top Parkinson Disease Drug Players by Revenue (2019-2024); 6.1.2 Global Parkinson Disease Drug Revenue Market Share by Players (2019-2024); 6.2 Global Parkinson Disease Drug Industry Players Ranking, 2022 VS 2023 VS 2024; 6.3 Global Key Players of Parkinson Disease Drug Head office and Area Served; 6.4 Global Parkinson Disease Drug Players, Product Type & Application; 6.5 Global Parkinson Disease Drug Players, Date of Enter into This Industry; 6.6 Global Parkinson Disease Drug Market CR5 and HHI; 6.7 Global Players Mergers & Acquisition
7 North America: 7.1 North America Parkinson Disease Drug Market Size (2019-2030); 7.2 North America Parkinson Disease Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030; 7.3 North America Parkinson Disease Drug Market Size by Country (2019-2024); 7.4 North America Parkinson Disease Drug Market Size by Country (2025-2030); 7.5 United States; 7.6 Canada
8 Europe: 8.1 Europe Parkinson Disease Drug Market Size (2019-2030); 8.2 Europe Parkinson Disease Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030; 8.3 Europe Parkinson Disease Drug Market Size by Country (2019-2024); 8.4 Europe Parkinson Disease Drug Market Size by Country (2025-2030); 7.4 Germany; 7.5 France; 7.6 U.K.; 7.7 Italy; 7.8 Russia; 7.9 Nordic Countries
9 Asia-Pacific: 9.1 Asia-Pacific Parkinson Disease Drug Market Size (2019-2030); 9.2 Asia-Pacific Parkinson Disease Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030; 9.3 Asia-Pacific Parkinson Disease Drug Market Size by Country (2019-2024); 9.4 Asia-Pacific Parkinson Disease Drug Market Size by Country (2025-2030); 8.4 China; 8.5 Japan; 8.6 South Korea; 8.7 Southeast Asia; 8.8 India; 8.9 Australia
10 Latin America: 10.1 Latin America Parkinson Disease Drug Market Size (2019-2030); 10.2 Latin America Parkinson Disease Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030; 10.3 Latin America Parkinson Disease Drug Market Size by Country (2019-2024); 10.4 Latin America Parkinson Disease Drug Market Size by Country (2025-2030); 9.4 Mexico; 9.5 Brazil
11 Middle East & Africa: 11.1 Middle East & Africa Parkinson Disease Drug Market Size (2019-2030); 11.2 Middle East & Africa Parkinson Disease Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030; 11.3 Middle East & Africa Parkinson Disease Drug Market Size by Country (2019-2024); 11.4 Middle East & Africa Parkinson Disease Drug Market Size by Country (2025-2030); 10.4 Turkey; 10.5 Saudi Arabia; 10.6 UAE
12 Players Profiled: 11.1 Merck; 11.1.1 Merck Company Detail; 11.1.2 Merck Business Overview; 11.1.3 Merck Parkinson Disease Drug Introduction; 11.1.4 Merck Revenue in Parkinson Disease Drug Business (2017-2022); 11.1.5 Merck Recent Development; 11.2 Akorn; 11.2.1 Akorn Company Detail; 11.2.2 Akorn Business Overview; 11.2.3 Akorn Parkinson Disease Drug Introduction; 11.2.4 Akorn Revenue in Parkinson Disease Drug Business (2017-2022); 11.2.5 Akorn Recent Development; 11.3 GSK; 11.3.1 GSK Company Detail; 11.3.2 GSK Business Overview; 11.3.3 GSK Parkinson Disease Drug Introduction; 11.3.4 GSK Revenue in Parkinson Disease Drug Business (2017-2022); 11.3.5 GSK Recent Development; 11.4 Novartis; 11.4.1 Novartis Company Detail; 11.4.2 Novartis Business Overview; 11.4.3 Novartis Parkinson Disease Drug Introduction; 11.4.4 Novartis Revenue in Parkinson Disease Drug Business (2017-2022); 11.4.5 Novartis Recent Development; 11.5 Boehringer Ingelheim; 11.5.1 Boehringer Ingelheim Company Detail; 11.5.2 Boehringer Ingelheim Business Overview; 11.5.3 Boehringer Ingelheim Parkinson Disease Drug Introduction; 11.5.4 Boehringer Ingelheim Revenue in Parkinson Disease Drug Business (2017-2022); 11.5.5 Boehringer Ingelheim Recent Development; 11.6 Teva Pharmaceutical; 11.6.1 Teva Pharmaceutical Company Detail; 11.6.2 Teva Pharmaceutical Business Overview; 11.6.3 Teva Pharmaceutical Parkinson Disease Drug Introduction; 11.6.4 Teva Pharmaceutical Revenue in Parkinson Disease Drug Business (2017-2022); 11.6.5 Teva Pharmaceutical Recent Development; 11.7 Abbvie; 11.7.1 Abbvie Company Detail; 11.7.2 Abbvie Business Overview; 11.7.3 Abbvie Parkinson Disease Drug Introduction; 11.7.4 Abbvie Revenue in Parkinson Disease Drug Business (2017-2022); 11.7.5 Abbvie Recent Development; 11.8 Kyowa Hakko Kirin Pharma; 11.8.1 Kyowa Hakko Kirin Pharma Company Detail; 11.8.2 Kyowa Hakko Kirin Pharma Business Overview; 11.8.3 Kyowa Hakko Kirin Pharma Parkinson Disease Drug Introduction; 11.8.4 Kyowa Hakko Kirin Pharma Revenue in Parkinson Disease Drug Business (2017-2022); 11.8.5 Kyowa Hakko Kirin Pharma Recent Development; 11.9 Astellas Pharma; 11.9.1 Astellas Pharma Company Detail; 11.9.2 Astellas Pharma Business Overview; 11.9.3 Astellas Pharma Parkinson Disease Drug Introduction; 11.9.4 Astellas Pharma Revenue in Parkinson Disease Drug Business (2017-2022); 11.9.5 Astellas Pharma Recent Development; 11.10 Desitin Arzneimittel; 11.10.1 Desitin Arzneimittel Company Detail; 11.10.2 Desitin Arzneimittel Business Overview; 11.10.3 Desitin Arzneimittel Parkinson Disease Drug Introduction; 11.10.4 Desitin Arzneimittel Revenue in Parkinson Disease Drug Business (2017-2022); 11.10.5 Desitin Arzneimittel Recent Development; 11.11 Endo Pharmaceuticals; 11.11.1 Endo Pharmaceuticals Company Detail; 11.11.2 Endo Pharmaceuticals Business Overview; 11.11.3 Endo Pharmaceuticals Parkinson Disease Drug Introduction; 11.11.4 Endo Pharmaceuticals Revenue in Parkinson Disease Drug Business (2017-2022); 11.11.5 Endo Pharmaceuticals Recent Development; 11.12 F.Hoffmann-La Roche; 11.12.1 F.Hoffmann-La Roche Company Detail; 11.12.2 F.Hoffmann-La Roche Business Overview; 11.12.3 F.Hoffmann-La Roche Parkinson Disease Drug Introduction; 11.12.4 F.Hoffmann-La Roche Revenue in Parkinson Disease Drug Business (2017-2022); 11.12.5 F.Hoffmann-La Roche Recent Development; 11.13 H.Lundbeck; 11.13.1 H.Lundbeck Company Detail; 11.13.2 H.Lundbeck Business Overview; 11.13.3 H.Lundbeck Parkinson Disease Drug Introduction; 11.13.4 H.Lundbeck Revenue in Parkinson Disease Drug Business (2017-2022); 11.13.5 H.Lundbeck Recent Development; 11.14 Valeant; 11.14.1 Valeant Company Detail; 11.14.2 Valeant Business Overview; 11.14.3 Valeant Parkinson Disease Drug Introduction; 11.14.4 Valeant Revenue in Parkinson Disease Drug Business (2017-2022); 11.14.5 Valeant Recent Development; 11.15 Apokyn; 11.15.1 Apokyn Company Detail; 11.15.2 Apokyn Business Overview; 11.15.3 Apokyn Parkinson Disease Drug Introduction; 11.15.4 Apokyn Revenue in Parkinson Disease Drug Business (2017-2022); 11.15.5 Apokyn Recent Development; 11.16 Orion; 11.16.1 Orion Company Detail; 11.16.2 Orion Business Overview; 11.16.3 Orion Parkinson Disease Drug Introduction; 11.16.4 Orion Revenue in Parkinson Disease Drug Business (2017-2022); 11.16.5 Orion Recent Development; 11.17 Stada Arzneimittel; 11.17.1 Stada Arzneimittel Company Detail; 11.17.2 Stada Arzneimittel Business Overview; 11.17.3 Stada Arzneimittel Parkinson Disease Drug Introduction; 11.17.4 Stada Arzneimittel Revenue in Parkinson Disease Drug Business (2017-2022); 11.17.5 Stada Arzneimittel Recent Development; 11.18 US WorldMeds; 11.18.1 US WorldMeds Company Detail; 11.18.2 US WorldMeds Business Overview; 11.18.3 US WorldMeds Parkinson Disease Drug Introduction; 11.18.4 US WorldMeds Revenue in Parkinson Disease Drug Business (2017-2022); 11.18.5 US WorldMeds Recent Development; 11.19 Bausch Health; 11.19.1 Bausch Health Company Detail; 11.19.2 Bausch Health Business Overview; 11.19.3 Bausch Health Parkinson Disease Drug Introduction; 11.19.4 Bausch Health Revenue in Parkinson Disease Drug Business (2017-2022); 11.19.5 Bausch Health Recent Development
13 Report Conclusion
14 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2019 VS 2023 VS 2030) & (US$ Million)
Table 4. Market Value Comparison by Application (2019 VS 2023 VS 2030) & (US$ Million)
Table 5. Global Parkinson Disease Drug Market Size by Type (2019-2024) & (US$ Million)
Table 6. Global Parkinson Disease Drug Revenue Market Share by Type (2019-2024)
Table 7. Global Parkinson Disease Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 8. Global Parkinson Disease Drug Revenue Market Share by Type (2025-2030)
Table 9. Global Parkinson Disease Drug Market Size by Application (2019-2024) & (US$ Million)
Table 10. Global Parkinson Disease Drug Revenue Market Share by Application (2019-2024)
Table 11. Global Parkinson Disease Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 12. Global Parkinson Disease Drug Revenue Market Share by Application (2025-2030)
Table 13. Global Parkinson Disease Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 14. Global Parkinson Disease Drug Market Size by Region (2019-2024) & (US$ Million)
Table 15. Global Parkinson Disease Drug Market Share by Region (2019-2024)
Table 16. Global Parkinson Disease Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 17. Global Parkinson Disease Drug Market Share by Region (2025-2030)
Table 18. Parkinson Disease Drug Market Trends
Table 19. Parkinson Disease Drug Market Drivers
Table 20. Parkinson Disease Drug Market Challenges
Table 21. Parkinson Disease Drug Market Restraints
Table 22. Global Top Parkinson Disease Drug Manufacturers by Revenue (US$ Million) & (2019-2024)
Table 23. Global Parkinson Disease Drug Revenue Market Share by Manufacturers (2019-2024)
Table 24. Global Parkinson Disease Drug Industry Manufacturers Ranking, 2022 VS 2023 VS 2024
Table 25. Global Key Players of Parkinson Disease Drug, Headquarters and Area Served
Table 26. Global Parkinson Disease Drug Manufacturers, Product Type & Application
Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Parkinson Disease Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. North America Parkinson Disease Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. North America Parkinson Disease Drug Market Size by Country (2019-2024) & (US$ Million)
Table 32. North America Parkinson Disease Drug Market Size by Country (2025-2030) & (US$ Million)
Table 33. Europe Parkinson Disease Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 34. Europe Parkinson Disease Drug Market Size by Country (2019-2024) & (US$ Million)
Table 35. Europe Parkinson Disease Drug Market Size by Country (2025-2030) & (US$ Million)
Table 36. Asia-Pacific Parkinson Disease Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 37. Asia-Pacific Parkinson Disease Drug Market Size by Country (2019-2024) & (US$ Million)
Table 38. Asia-Pacific Parkinson Disease Drug Market Size by Country (2025-2030) & (US$ Million)
Table 39. Latin America Parkinson Disease Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 40. Latin America Parkinson Disease Drug Market Size by Country (2019-2024) & (US$ Million)
Table 41. Latin America Parkinson Disease Drug Market Size by Country (2025-2030) & (US$ Million)
Table 42. Middle East & Africa Parkinson Disease Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 43. Middle East & Africa Parkinson Disease Drug Market Size by Country (2019-2024) & (US$ Million)
Table 44. Middle East & Africa Parkinson Disease Drug Market Size by Country (2025-2030) & (US$ Million)
Table 45. Merck Company Detail
Table 46. Merck Business Overview
Table 47. Merck Parkinson Disease Drug Product
Table 48. Merck Revenue in Parkinson Disease Drug Business (2017-2022) & (US$ Million)
Table 49. Merck Recent Development
Table 50. Akorn Company Detail
Table 51. Akorn Business Overview
Table 52. Akorn Parkinson Disease Drug Product
Table 53. Akorn Revenue in Parkinson Disease Drug Business (2017-2022) & (US$ Million)
Table 54. Akorn Recent Development
Table 55. GSK Company Detail
Table 56. GSK Business Overview
Table 57. GSK Parkinson Disease Drug Product
Table 58. GSK Revenue in Parkinson Disease Drug Business (2017-2022) & (US$ Million)
Table 59. GSK Recent Development
Table 60. Novartis Company Detail
Table 61. Novartis Business Overview
Table 62. Novartis Parkinson Disease Drug Product
Table 63. Novartis Revenue in Parkinson Disease Drug Business (2017-2022) & (US$ Million)
Table 64. Novartis Recent Development
Table 65. Boehringer Ingelheim Company Detail
Table 66. Boehringer Ingelheim Business Overview
Table 67. Boehringer Ingelheim Parkinson Disease Drug Product
Table 68. Boehringer Ingelheim Revenue in Parkinson Disease Drug Business (2017-2022) & (US$ Million)
Table 69. Boehringer Ingelheim Recent Development
Table 70. Teva Pharmaceutical Company Detail
Table 71. Teva Pharmaceutical Business Overview
Table 72. Teva Pharmaceutical Parkinson Disease Drug Product
Table 73. Teva Pharmaceutical Revenue in Parkinson Disease Drug Business (2017-2022) & (US$ Million)
Table 74. Teva Pharmaceutical Recent Development
Table 75. Abbvie Company Detail
Table 76. Abbvie Business Overview
Table 77. Abbvie Parkinson Disease Drug Product
Table 78. Abbvie Revenue in Parkinson Disease Drug Business (2017-2022) & (US$ Million)
Table 79. Abbvie Recent Development
Table 80. Kyowa Hakko Kirin Pharma Company Detail
Table 81. Kyowa Hakko Kirin Pharma Business Overview
Table 82. Kyowa Hakko Kirin Pharma Parkinson Disease Drug Product
Table 83. Kyowa Hakko Kirin Pharma Revenue in Parkinson Disease Drug Business (2017-2022) & (US$ Million)
Table 84. Kyowa Hakko Kirin Pharma Recent Development
Table 85. Astellas Pharma Company Detail
Table 86. Astellas Pharma Business Overview
Table 87. Astellas Pharma Parkinson Disease Drug Product
Table 88. Astellas Pharma Revenue in Parkinson Disease Drug Business (2017-2022) & (US$ Million)
Table 89. Astellas Pharma Recent Development
Table 90. Desitin Arzneimittel Company Detail
Table 91. Desitin Arzneimittel Business Overview
Table 92. Desitin Arzneimittel Parkinson Disease Drug Product
Table 93. Desitin Arzneimittel Revenue in Parkinson Disease Drug Business (2017-2022) & (US$ Million)
Table 94. Desitin Arzneimittel Recent Development
Table 95. Endo Pharmaceuticals Company Detail
Table 96. Endo Pharmaceuticals Business Overview
Table 97. Endo Pharmaceuticals Parkinson Disease DrugProduct
Table 98. Endo Pharmaceuticals Revenue in Parkinson Disease Drug Business (2017-2022) & (US$ Million)
Table 99. Endo Pharmaceuticals Recent Development
Table 100. F.Hoffmann-La Roche Company Detail
Table 101. F.Hoffmann-La Roche Business Overview
Table 102. F.Hoffmann-La Roche Parkinson Disease DrugProduct
Table 103. F.Hoffmann-La Roche Revenue in Parkinson Disease Drug Business (2017-2022) & (US$ Million)
Table 104. F.Hoffmann-La Roche Recent Development
Table 105. H.Lundbeck Company Detail
Table 106. H.Lundbeck Business Overview
Table 107. H.Lundbeck Parkinson Disease DrugProduct
Table 108. H.Lundbeck Revenue in Parkinson Disease Drug Business (2017-2022) & (US$ Million)
Table 109. H.Lundbeck Recent Development
Table 110. Valeant Company Detail
Table 111. Valeant Business Overview
Table 112. Valeant Parkinson Disease DrugProduct
Table 113. Valeant Revenue in Parkinson Disease Drug Business (2017-2022) & (US$ Million)
Table 114. Valeant Recent Development
Table 115. Apokyn Company Detail
Table 116. Apokyn Business Overview
Table 117. Apokyn Parkinson Disease DrugProduct
Table 118. Apokyn Revenue in Parkinson Disease Drug Business (2017-2022) & (US$ Million)
Table 119. Apokyn Recent Development
Table 120. Orion Company Detail
Table 121. Orion Business Overview
Table 122. Orion Parkinson Disease DrugProduct
Table 123. Orion Revenue in Parkinson Disease Drug Business (2017-2022) & (US$ Million)
Table 124. Orion Recent Development
Table 125. Stada Arzneimittel Company Detail
Table 126. Stada Arzneimittel Business Overview
Table 127. Stada Arzneimittel Parkinson Disease DrugProduct
Table 128. Stada Arzneimittel Revenue in Parkinson Disease Drug Business (2017-2022) & (US$ Million)
Table 129. Stada Arzneimittel Recent Development
Table 130. US WorldMeds Company Detail
Table 131. US WorldMeds Business Overview
Table 132. US WorldMeds Parkinson Disease DrugProduct
Table 133. US WorldMeds Revenue in Parkinson Disease Drug Business (2017-2022) & (US$ Million)
Table 134. US WorldMeds Recent Development
Table 135. Bausch Health Company Detail
Table 136. Bausch Health Business Overview
Table 137. Bausch Health Parkinson Disease DrugProduct
Table 138. Bausch Health Revenue in Parkinson Disease Drug Business (2017-2022) & (US$ Million)
Table 139. Bausch Health Recent Development
Table 140. Merck Company Information
Table 141. Merck Business Overview
Table 142. Merck Parkinson Disease Drug Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
Table 143. Merck Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million) Portfolio
Table 144. Merck Recent Development
Table 145. Akorn Company Information
Table 146. Akorn Business Overview
Table 147. Akorn Parkinson Disease Drug Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
Table 148. Akorn Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million) Portfolio
Table 149. Akorn Recent Development
Table 150. GSK Company Information
Table 151. GSK Business Overview
Table 152. GSK Parkinson Disease Drug Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
Table 153. GSK Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million) Portfolio
Table 154. GSK Recent Development
Table 155. Novartis Company Information
Table 156. Novartis Business Overview
Table 157. Novartis Parkinson Disease Drug Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
Table 158. Novartis Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million) Portfolio
Table 159. Novartis Recent Development
Table 160. Boehringer Ingelheim Company Information
Table 161. Boehringer Ingelheim Business Overview
Table 162. Boehringer Ingelheim Parkinson Disease Drug Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
Table 163. Boehringer Ingelheim Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million) Portfolio
Table 164. Boehringer Ingelheim Recent Development
Table 165. Teva Pharmaceutical Company Information
Table 166. Teva Pharmaceutical Business Overview
Table 167. Teva Pharmaceutical Parkinson Disease Drug Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
Table 168. Teva Pharmaceutical Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million) Portfolio
Table 169. Teva Pharmaceutical Recent Development
Table 170. Abbvie Company Information
Table 171. Abbvie Business Overview
Table 172. Abbvie Parkinson Disease Drug Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
Table 173. Abbvie Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million) Portfolio
Table 174. Abbvie Recent Development
Table 175. Kyowa Hakko Kirin Pharma Company Information
Table 176. Kyowa Hakko Kirin Pharma Business Overview
Table 177. Kyowa Hakko Kirin Pharma Parkinson Disease Drug Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
Table 178. Kyowa Hakko Kirin Pharma Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million) Portfolio
Table 179. Kyowa Hakko Kirin Pharma Recent Development
Table 180. Astellas Pharma Company Information
Table 181. Astellas Pharma Business Overview
Table 182. Astellas Pharma Parkinson Disease Drug Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
Table 183. Astellas Pharma Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million) Portfolio
Table 184. Astellas Pharma Recent Development
Table 185. Desitin Arzneimittel Company Information
Table 186. Desitin Arzneimittel Business Overview
Table 187. Desitin Arzneimittel Parkinson Disease Drug Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
Table 188. Desitin Arzneimittel Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million) Portfolio
Table 189. Desitin Arzneimittel Recent Development
Table 190. Endo Pharmaceuticals Company Information
Table 191. Endo Pharmaceuticals Business Overview
Table 192. Endo Pharmaceuticals Parkinson Disease DrugRevenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
Table 193. Endo Pharmaceuticals Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million) Portfolio
Table 194. Endo Pharmaceuticals Recent Development
Table 195. F.Hoffmann-La Roche Company Information
Table 196. F.Hoffmann-La Roche Business Overview
Table 197. F.Hoffmann-La Roche Parkinson Disease DrugRevenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
Table 198. F.Hoffmann-La Roche Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million) Portfolio
Table 199. F.Hoffmann-La Roche Recent Development
Table 200. H.Lundbeck Company Information
Table 201. H.Lundbeck Business Overview
Table 202. H.Lundbeck Parkinson Disease DrugRevenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
Table 203. H.Lundbeck Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million) Portfolio
Table 204. H.Lundbeck Recent Development
Table 205. Valeant Company Information
Table 206. Valeant Business Overview
Table 207. Valeant Parkinson Disease DrugRevenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
Table 208. Valeant Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million) Portfolio
Table 209. Valeant Recent Development
Table 210. Apokyn Company Information
Table 211. Apokyn Business Overview
Table 212. Apokyn Parkinson Disease DrugRevenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
Table 213. Apokyn Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million) Portfolio
Table 214. Apokyn Recent Development
Table 215. Orion Company Information
Table 216. Orion Business Overview
Table 217. Orion Parkinson Disease DrugRevenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
Table 218. Orion Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million) Portfolio
Table 219. Orion Recent Development
Table 220. Stada Arzneimittel Company Information
Table 221. Stada Arzneimittel Business Overview
Table 222. Stada Arzneimittel Parkinson Disease DrugRevenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
Table 223. Stada Arzneimittel Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million) Portfolio
Table 224. Stada Arzneimittel Recent Development
Table 225. US WorldMeds Company Information
Table 226. US WorldMeds Business Overview
Table 227. US WorldMeds Parkinson Disease DrugRevenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
Table 228. US WorldMeds Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million) Portfolio
Table 229. US WorldMeds Recent Development
Table 230. Bausch Health Company Information
Table 231. Bausch Health Business Overview
Table 232. Bausch Health Parkinson Disease DrugRevenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
Table 233. Bausch Health Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million) Portfolio